In situ blood-brain barrier transport of nanoparticles
- PMID: 14661921
- DOI: 10.1023/b:pham.0000003374.58641.62
In situ blood-brain barrier transport of nanoparticles
Abstract
Purpose: Two novel types of nanoparticles were evaluated as poten tial carriers for drugs across the blood-brain barrier (BBB).
Methods: Nanoparticles were composed of biocompatible materials including emulsifying wax (E. Wax) or Brij 72. Brij 78 and Tween 80 were used as surfactants for E. Wax nanoparticles (E78 NPs) and Brij 72 nanoparticles (E72 NPs), respectively. Both nanoparticle formulations were prepared from warm microemulsion precursors usin melted E. Wax or Brij 72 as the oil phase. Nanoparticles were radio-labeled by entrapment of [3H]cetyl alcohol, and entrapment efficiency and release of radiolabel were evaluated. The transport of E78 and E72 NPs across the BBB was measured by an in situ rat brai perfusion method.
Results: Both formulations were successfully radiolabeled by entrapment of [3H]cetyl alcohol; -98% of radiolabel remained associated with nanoparticles at experimental conditions. The transfer rate (Kin) of E78 NPs from perfusion fluid into the brain was 4.1 +/- 0.5 x 10(-3) ml/s/g, and the permeability-surface area product (PA) was 4.3 +/- 0.7 x 10(-3) ml/s/g. The values for Kin and PA for E72 NPs were 5.7 +/- 1.1 x 10(-3) ml/s/g and 6.1 +/- 1.4 x 10(-3) ml/s/g, respectively.
Conclusions: For both nanoparticle types, statistically significant uptake was observed compared to [14C]sucrose, suggesting central nervous system uptake of nanoparticles. The mechanism underlying th nanoparticle brain uptake has yet to be fully understood.
Similar articles
-
Brain uptake of thiamine-coated nanoparticles.J Control Release. 2003 Dec 12;93(3):271-82. doi: 10.1016/j.jconrel.2003.08.006. J Control Release. 2003. PMID: 14644577
-
Nanoparticle surface charges alter blood-brain barrier integrity and permeability.J Drug Target. 2004;12(9-10):635-41. doi: 10.1080/10611860400015936. J Drug Target. 2004. PMID: 15621689
-
In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles.Pharm Res. 2003 May;20(5):705-13. doi: 10.1023/a:1023492015851. Pharm Res. 2003. PMID: 12751624
-
Transport of drugs across the blood-brain barrier by nanoparticles.J Control Release. 2012 Jul 20;161(2):264-73. doi: 10.1016/j.jconrel.2011.08.017. Epub 2011 Aug 18. J Control Release. 2012. PMID: 21872624 Review.
-
Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection.J Neuroimmune Pharmacol. 2017 Mar;12(1):31-50. doi: 10.1007/s11481-016-9692-7. Epub 2016 Jul 2. J Neuroimmune Pharmacol. 2017. PMID: 27372507 Free PMC article. Review.
Cited by
-
Brain microvascular endothelial cell association and distribution of a 5 nm ceria engineered nanomaterial.Int J Nanomedicine. 2012;7:4023-36. doi: 10.2147/IJN.S32526. Epub 2012 Jul 27. Int J Nanomedicine. 2012. PMID: 22888240 Free PMC article.
-
Hesperidin alleviates zinc oxide nanoparticle induced hepatotoxicity and oxidative stress.BMC Pharmacol Toxicol. 2018 Oct 19;19(1):65. doi: 10.1186/s40360-018-0256-8. BMC Pharmacol Toxicol. 2018. PMID: 30340509 Free PMC article.
-
The effect of the serum corona on interactions between a single nano-object and a living cell.Sci Rep. 2017 Apr 6;7:45758. doi: 10.1038/srep45758. Sci Rep. 2017. PMID: 28383528 Free PMC article.
-
Manufactured aluminum oxide nanoparticles decrease expression of tight junction proteins in brain vasculature.J Neuroimmune Pharmacol. 2008 Dec;3(4):286-95. doi: 10.1007/s11481-008-9131-5. Epub 2008 Oct 1. J Neuroimmune Pharmacol. 2008. PMID: 18830698 Free PMC article.
-
Ergosterol-loaded poly(lactide-co-glycolide) nanoparticles with enhanced in vitro antitumor activity and oral bioavailability.Acta Pharmacol Sin. 2016 Jun;37(6):834-44. doi: 10.1038/aps.2016.37. Epub 2016 May 2. Acta Pharmacol Sin. 2016. PMID: 27133301 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources